Exelixis (EXEL) Income from Continuing Operations (2010 - 2026)

Exelixis (EXEL) recorded quarterly Income from Continuing Operations of 210467000.0 in Q2 2026, down 13.93% quarter-over-quarter from 244528000.0 in Q1 2026, and up 31.86% on a YoY basis from 159616000.0 in Q2 2025.

Exelixis (EXEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Exelixis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 210467000.0 for Q2 2026.

  • In Q2 2026, Income from Continuing Operations rose 31.86% year-over-year to 210467000.0; the TTM figure through Apr 2026 stood at 833421000.0 (up 29.5% YoY), while the FY2026 annual figure was 782570000.0, up 50.13% from the prior year.
  • Income from Continuing Operations was 210467000.0 for Q2 2026 at Exelixis, down from 244528000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 244528000.0 in Q1 2026 to a low of 30173000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 112020647.06 across 5 years, with a median of 85518000.0 in 2023.
  • The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 131.71% in 2022, then jumped 11232.66% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 30173000.0 in 2022, then surged by 383.43% to 85518000.0 in 2023, then jumped by 37.95% to 117973000.0 in 2024, then jumped by 64.09% to 193578000.0 in 2025, then increased by 8.72% to 210467000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 210467000.0 (Q2 2026), 244528000.0 (Q1 2026), and 193578000.0 (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -2.97 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 30.80 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -14.46 Mn
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -3.40 Mn
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 1.03 Bn
9 Abivax 95.45 Bn 95.45 Bn - -56.48 Mn
10 Exelixis 13.71 Bn 12.93 Bn 590.86 Mn 210.47 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 210.47 Mn
Jan 2, 2026 244.53 Mn
Oct 3, 2025 193.58 Mn
Jul 4, 2025 184.85 Mn
Apr 4, 2025 159.62 Mn
Jan 3, 2025 139.86 Mn
Sep 27, 2024 117.97 Mn
Jun 28, 2024 226.12 Mn
Mar 29, 2024 37.32 Mn
Dec 29, 2023 85.52 Mn
Sep 29, 2023 1.04 Mn
Jun 30, 2023 81.18 Mn
Mar 31, 2023 40.03 Mn
Dec 30, 2022 -30.17 Mn
Sep 30, 2022 73.21 Mn
Jul 1, 2022 70.67 Mn
Apr 1, 2022 68.57 Mn
Dec 31, 2021 95.17 Mn
Oct 1, 2021 38.20 Mn
Jul 2, 2021 96.09 Mn